Interplay of iron metallobiology, metalloproteinases, and FXIII, and role of their gene variants in venous leg ulcer

International Journal of Lower Extremity Wounds

Volumn 9, Issue 4, 2010, Pages 166-179

  Singh, Ajay V ^a,b   Subhashree, L ^b   Milani, Paolo ^c   Gemmati, Donato ^d   Zamboni, Paolo ^e  

^a European School of Molecular Medicine SEMM   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c STES's Smt Kashibai Navale College of Pharmacy   (India)

^d Fondazione Filarete   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

extracellular matrix; metalloproteinases; single nucleotide polymorphisms; venous ulcers

Indexed keywords

BLOOD CLOTTING FACTOR 13; FERROPORTIN 1; FREE RADICAL; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; ARTICLE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALING IMPAIRMENT; HEMOCHROMATOSIS; HOMEOSTASIS; HUMAN; IRON OVERLOAD; LEG ULCER; MICROCIRCULATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE REGENERATION; WOUND HEALING;

ANTI-INFECTIVE AGENTS; EXTRACELLULAR MATRIX; FACTOR XIII; GENETIC VARIATION; GUIDED TISSUE REGENERATION; HUMANS; INFLAMMATION; IRON; IRON OVERLOAD; METALLOPROTEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REACTIVE OXYGEN SPECIES; VARICOSE ULCER; WOUND HEALING;

EID: 78650384117     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734610384653     Document Type: Article

References (102)

1. Clark AG, Miller AL, Vaughan E., Yu HY, Penkert R., Bement WM Integration of single and multicellular wound responses. Curr Biol. 2009 ; 19: 1389-1395.
2. Bauer AL, Jackson TL, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol. 2009 ; 5: e1000445.
3. Eming SE, Krieg T., Davidson JM Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007 ; 127: 514-525.
4. Simka M. Cellular and molecular mechanisms of venous leg ulcers development-the "puzzle" theory. Int Angiol. 2010 ; 29: 1-19.
5. McDonagh J., Fukue H. Determinants of substrate specificity for factor XIII. Thromb Hemost. 1996 ; 22: 369-376.
6. Muszbek L., Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999 ; 94: 271-305.
7. Mosher DF, Vaheri A. Binding and degradation of alpha 2-macroglobulin by cultured fibroblasts. Biochim Biophys Acta. 1980 ; 627: 113-122.
8. Ueyama M., Urayama T. The role of factor XIII in fibroblast proliferation. Jpn J Exp Med. 1978 ; 48: 135-142.
9. Bruhn HD, Pohl J. Growth regulation of fibroblasts by thrombin, factor XIII and fibronectin. Klin Wochenschr. 1981 ; 59: 145-146.
10. Zamboni P., De Mattei M., Ongaro A., et al. Factor XIII contrasts the effects of metalloproteinases in human dermal fibroblast cultured cells. Vasc Endovascular Surg. 2004 ; 38: 413-438.
11. Andrews NC Disorders of iron metabolism. N Engl J Med. 1999 ; 341: 1986-1995.
12. Chua ACG, Graham RM, Trinder D., Olynyk JK The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci. 2007 ; 44: 413-459.
13. Messer JG, Kilbarger AK, Erikson KM, Kipp DE Iron overload alters iron-regulatory genes and proteins, down-regulates osteoblastic phenotype, and is associated with apoptosis in fetal rat calvaria cultures. Bone. 2009 ; 45: 972-979.
14. Raju S., Neglén P. Clinical practice. Chronic venous insufficiency and varicose veins. N Engl J Med. 2009 ; 360: 2319-2327.
15. Zamboni P., Lanzara S., Mascoli F., Caggiati A., Liboni A. Inflammation in venous disease. Int Angiol. 2008 ; 27: 361-369.
16. Zamboni P., Izzo M., Fogato L., Carandina S., Lanzara V. Urine haemosiderin: a novel marker to assess the severity of chronic venous disease. J Vasc Surg. 2003 ; 37: 132-136.
17. Wenk J., Foitzik A., Achterberg V., et al. Selective pick-up of increased iron by deferoxamine-coupled cellulose abrogates the iron-driven induction of matrix degrading metalloproteinase 1 and lipid peroxidation in human dermal fibroblasts in vitro: a new dressing concept. J Invest Dermatol. 2001 ; 116: 833-839.
18. Ackerman Z., Seidenbaum M., Loewenthal E., Rubinow A. Overload of iron in the skin of patients with varicose ulcers. Possible contributing role of iron accumulation in progression of the disease. Arch Dermatol. 1988 ; 124: 1376-1378.
19. Herrick SE, Treharne LJ, deGiorgio-Miller AM Dermal changes in the lower leg skin of patients with venous hypertension. Int J Low Extrem Wounds. 2002 ; 1: 80-86.
20. Bruce AJ, Bennett DD, Lohse CM, Rooke TW, Davis MD Lipodermatosclerosis: review of cases evaluated at Mayo Clinic. J Am Acad Dermatol. 2002 ; 46: 187-192.
21. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med. 2006 ; 99: 589-593.
22. Perls M. Nachweis von Eisenoxyd in gewissen Pigmenten [in German]. Virchows Arch F Pathol Anat. 1867 ; 39: 42-48.
23. Piconi L., Quagliaro L., Da Ros R., et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost. 2004 ; 2: 1453-1459.
24. Wilkinson LS, Bunker C., Edwards JC, Scurr JH, Smith PD Leukocytes: their role in the etiopathogenesis of skin damage in venous disease. J Vasc Surg. 1993 ; 17: 669-675.
25. Raffetto JD Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res. 2009 ; 123: 66-71.
26. Yeoh-Ellerton S., Stacey MC Iron and 8-isoprostane levels in acute and chronic wounds. J Invest Dermatol. 2003 ; 121: 918-925.
27. Allhorn M., Lundqvist K., Schmidtchen A., Akerström B. Heme-scavenging role of alpha1-microglobulin in chronic ulcers. J Invest Dermatol. 2003 ; 121: 640-646.
28. Hoffman M. Animal models of bleeding and tissue repair. Haemophilia. 2008 ; 14: 62-67.
29. Halliwell B. The wanderings of a free radical. Free Radic Biol Med. 2009 ; 46: 531-542.
30. Schwarz P., Strnad P., Singer N., et al. Identification, sequencing, and cellular localization of hepcidin in guinea pig (Cavia porcellus). J Endocrinol. 2009 ; 202: 389-396.
31. Ganz T., Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006 ; 290: 199-203.
32. Nemeth E., Tuttle MS, Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004 ; 306: 2090-2093.
33. Weigelt C., Rose B., Poschen U., et al. Immune mediators in patients with acute diabetic foot syndrome. Diabetes Care. 2009 ; 32: 1491-1496.
34. Gurjar MV, Deleon J., Sharma RV, Bhalla RC Role of reactive oxygen species in IL-1 beta-stimulated sustained ERK activation and MMP-9 induction. Am J Physiol Heart Circ Physiol. 2001 ; 281: 2568-2574.
35. Zamboni P., Izzo M., Tognazzo S., et al. The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radic Biol Med. 2006 ; 40: 1869-1873.
36. Nick H., Allegrini PR, Fozard L., et al. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. Exp Biol Med (Maywood). 2009 ; 234: 492-503.
37. Janssen MC, Swinkels DW Hereditary haemochromatosis. Best Pract Res Clin Gastroenterol. 2009 ; 23: 171-183.
38. Halliwell B., Gutteridge JMC. Free Radicals in Biology and Medicine. 2 nd ed. Oxford, UK: Clarendon Press ; 1989.
39. Olszyski K., Zimowska M. Structure and function of matrix metalloproteinases. Postepy Biochem. 2009 ; 55: 76-84.
40. Holmbeck K., Bianco P., Caterina J., et al. MT1-MMP deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999 ; 99: 81-92.
41. Yan C., Boyd DD Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2006 ; 211: 19-26.
42. Van Lint P., Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol. 2007 ; 82: 1375-1381.
43. Nagase H., Woessner F. Matrix metalloproteinases. J Biol Chem. 1999 ; 274: 21491-21494.
44. Tallant C., Marrero A., Gomis-Rüth FX Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta. 2010 ; 1803: 20-28
45. Glaros T., Larsen M., Li L. Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front Biosci. 2009 ; 14: 3988-3993.
46. Harvima IT Induction of matrix metalloproteinase-9 in keratinocytes by histamine. J Invest Dermatol. 2008 ; 128: 2 748-2750.
47. Armstrong DG, Jude EB The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc. 2002 ; 92: 12-18.
48. Herrick S., Ashcroft G., Ireland G., Horan M., McCollum C., Ferguson M. Up-regulation of elastase in acute wounds of healthy aged humans and chronic venous leg ulcers are associated with matrix degradation. Lab Invest. 1997 ; 77: 281-288.
49. Brem H., Stojadinovic O., Diegelmann RF, et al. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med. 2007 ; 13: 30-39.
50. De Mattei M., Ongaro A., Magaldi S., et al. Time- and dose-dependent effects of chronic wound fluid on human adult dermal fibroblasts. Dermatol Surg. 2008 ; 34: 347-356.
51. Sossey-Alaoui K., Ranalli TA, Li X., Bakin AV, Cowell JK WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Exp Cell Res. 2005 ; 308: 135-145.
52. Uttara B., Singh AV, Zamboni P., Mahajan RT Neurodegenerative diseases and oxidative stress: review of upstream and downstream therapeutic options. Curr Neuropharmacol. 2009 ; 7: 78-84.
53. Zamboni P., Scapoli G., Lanzara V., et al. Serum iron and maxtrix metalloproteinase 9 variations in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg. 2005 ; 31: 19-22.
54. Garcia-Alloza M., Prada C., Lattarulo C., et al. Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J Neurochem. 2009 ; 109: 1636-1647.
55. Zoghbi HY, Daiger SP, McCall A., O'Brien WE, Beaudet AL Extensive DNA polymorphism at the factor XIIIa (F13A) locus and linkage to HLA. Am J Hum Genet. 1988 ; 42: 877-883.
56. Muszbek L., Adány R., Szegedi G., Polgár J., Kávai M. Factor XIII of blood coagulation in human monocytes. Thromb Res. 1985 ; 37: 401-410.
57. Henriksson P., Becker S., Lynch G., McDonagh J. Identification of intracellular factor XIII in human monocytes and macrophages. J Clin Invest. 1985 ; 76: 528-534.
58. Poon MC, Russell JA, Low S., et al. Hemopoietic origin of factor XIII A subunits in platelets, monocytes, and plasma. Evidence from bone marrow transplantation studies. J Clin Invest. 1989 ; 84: 787-792.
59. Nagy JA, Henriksson P., McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood. 1986 ; 68: 1272-1279.
60. Corbett SA, Lee L., Wilson CL, Schwarzbauer JE Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. J Biol Chem. 1997 ; 272: 24999-25005.
61. Gemmati D., Tognazzo S., Serino ML, et al. Factor XIII V34L polymorphism modulates the risk of chronic venous leg ulcer progression and extension. Wound Repair Regen. 2004 ; 12: 512-517.
62. Herouy Y., May AE, Pornschlegel G., et al. Lipoderamtosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol. 1998 ; 111: 822-827.
63. Vanscheidt W., Hasler K., Wokalek H., Niedner R., Schöpf E. Factor XIII-deficiency in the blood of venous leg ulcer patient. Acta Derm Venereol. 1991 ; 71: 55-57.
64. Dardik R., Loscalzo J., Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost. 2006 ; 4: 19-25.
65. Coffman LG, Parsonage D., D'Agostino R., Torti FM, Torti SV Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci. 2009 ; 106: 570-575.
66. Wozniak G., Dapper F., Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. Semin Thromb Hemostat. 1996 ; 22: 445-450.
67. Hildenbrand T., Idzko M., Panther E., Norgauer J., Herouy Y. Treatment of nonhealing leg ulcers with fibrin-stabilizing factor XIII: a case report. Dermatol Surg. 2002 ; 28: 1098-1099.
68. Inbal A., Lubetsky A., Krapp T., et al. Impaired wound healing in factor XIII deficient mice. Thromb Haemost. 2005 ; 94: 432-437.
69. Nahrendorf M., Hu K., Frantz S., et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodelling in mice with myocardial infarction. Circulation. 2006 ; 113: 1196-1202.
70. Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006 ; 355: 488-498.
71. Ruckley CV, Evans CJ, Allan PL, Lee AJ, Fowkes FG Chronic venous insufficiency: clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population. J Vasc Surg. 2002 ; 36: 520-525.
72. Heit JA, Rooke TW, Silverstein MD, et al. Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study. J Vasc Surg. 2001 ; 33: 1022-1027.
73. Sen CK, Gordillo GM, Roy S., et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009 ; 17: 763-771.
74. Nicolaides AN The international consensus group. The investigation of chronic venous insufficiency. A consensus statement. Circulation. 2000 ; 102: 126-163.
75. Coleridge Smith PD, Thomas P., Scurr JH, Dormandy JA Causes of venous ulceration: a new hypothesis. BMJ. 1988 ; 296: 1726-1727.
76. Zamboni P., Gemmati D. Clinical implications of gene polymorphisms in venous leg ulcer: A model in tissue injury and reparative process Thromb Haemost. 2007 ; 98: 131-137.
77. Zamboni P., Tognazzo S., Izzo M., et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg. 2005 ; 42: 309-314.
78. Ombiga J., Adams LA, Tang K., Trinder D., Olynyk JK Screening for HFE and iron overload. Semin Liver Dis. 2006 ; 25: 402-410.
79. Feder JN, Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet. 1996 ; 13: 399-408.
80. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative hemochromatosis mutation. J Med Genet. 1997 ; 34: 275-278.
81. Gochee PA, Powell LW, Cullen DJ, Du Sart D., Rossi E., Olynyk JK A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. 2002 ; 122: 646-651.
82. Mura C., Raguenes O., Ferec C. HFE mutation analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 1999 ; 93: 2502-2505.
83. Gross CN, Irrinki A., Feder JN, Enns CA Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the trasferrin receptor implies a role in intracellular iron regulation. J Biol Chem. 1998 ; 272: 22068-22074.
84. Waheed A., Parkkila S., Saarnio J., et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in cos-7 cells. Proc Natl Acad Sci. 1997 ; 94: 12384-12389.
85. Eklöf B., Rutherford RB, Bergan JJ, et al. American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. J Vasc Surg. 2004 ; 40: 1248-1252.
86. Donovan A., Brownlie A., Zhou Y., et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000 ; 403: 776-781.
87. Domenico I., Ward DM, Musci G., Kaplan J. Iron overload due to mutations in ferroportin. Haematologica. 2006 ; 91: 92-95.
88. Gemmati D., Federici F., Catozzi L., et al. DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators. J Vasc Surg. 2009 ; 50: 1444-1451.
89. Singh AV, Zamboni P. Anomalous venous blood flow and iron deposition in multiple sclerosis. J Cereb Blood Flow Metab. 2009 ; 29: 1867-1878.
90. Zamboni P., Menegatti E., Bartolomei I., et al. Intracranial venous haemodynamics in multiple sclerosis. Curr Neurovasc Res. 2007 ; 4: 252-258.
91. Simka M., Rybak Z. Hypothetical molecular mechanisms by which local iron overload facilitates the development of venous leg ulcers and multiple sclerosis lesions. Med Hypotheses. 2008 ; 71: 293-297.
92. Gemmati D., Tognazzo S., Catozzi L., et al. Influence of gene polymorphisms in ulcer healing process after superficial venous surgery. J Vasc Surg. 2006 ; 44: 554-562.
93. Tognazzo S., Gemmati D., Palazzo A., et al. Prognostic role of factor XIII gene variants in nonhealing venous leg ulcers. J Vasc Surg. 2006 ; 44: 815-819.
94. Anwar R., Gallivan L., Edmonds SD, Markham AF Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood. 1999 ; 93: 897-905.
95. Komanasin N., Catto AJ, Futers TS, van Hylckama VA, Rosendaal FR, Ariëns RA A novel polymorphism in factor XIII B-subunit(His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost. 2005 ; 3: 2487-2496.
96. Ariëns RA, Philippou H., Nagaswami C., Weisel JW, Lane DA, Grant PJ The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000 ; 96: 988-995.
97. Schröder V., Kohler HP Effect of FXIII Val34Leu on alpha-2-antiplasmin incorporation into fibrin. Thromb Haemost. 2000 ; 84: 1128-1130.
98. Yee VC, Pedersen LC, Le TI, Bishop PD, Stenkamp RE, Teller DC Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci. 1994 ; 91: 7296-7300.
99. Bereczky Z., Katona E., Muszbek L. Fibrin stabilization (factor XIII), fibrin structure and thrombosis. Pathophysiol Haemost Thromb. 2004 ; 33: 430-437.
100. Lamblin N., Bauters C., Hermant X., Lablanche JM, Helbecque N., Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurismal coronary artery disease. J Am Coll Cardiol. 2002 ; 40: 43-48.
101. Jormsjö S., Ye S., Moritz J., et al. Allele specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res. 2000 ; 86: 998-1003.
102. Zamboni P. Genetics of venous leg ulcer: an indication to priority of varicose veins treatment ? Int Angiol. 2008 ; 27: 91-92.